Shares of Bio-Techne Corp. advanced 7.39% to $50.91 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index falling 0.38% to 7,337.11 and Dow ...

Bio-Techne Corporation has released its third-quarter fiscal 2026 results, reporting sales of US$311.42 million and net income of US$51.05 million, alongside higher basic and diluted earnings per ...

Bio-Techne slips after Q3 EPS miss and revenue decline, despite operating margin expansion and strong growth in key segments.

Life sciences company Bio-Techne (NASDAQ:TECH) in Q1 CY2026, with sales falling 1.5% year on year to $311.4 million. Its ...

Bio-Techne TECH reported third-quarter fiscal 2025 adjusted earnings per share (EPS) of 56 cents, which surpassed the Zacks Consensus Estimate by 9.8%. The bottom line improved from the year-ago ...

Valued at a market cap of $9.3 billion, Bio-Techne Corporation (TECH) is a global life sciences company providing tools and bioactive reagents for the research and clinical diagnostic communities.

Bio-Techne is a leading provider of specialized reagents, analytical instruments, and diagnostic solutions for the life sciences and clinical diagnostics sectors. The company leverages a diverse ...

Techne (TECH) came out with quarterly earnings of $0.53 per share, missing the Zacks Consensus Estimate of $0.55 per share. This compares to earnings of $0.56 per share a year ago. These figures are ...

RBC Capital on Tuesday upgraded Bio-Techne Corporation (NASDAQ:TECH), noting that recent end-market weakness has over-penalized one of the best assets in the life science and tools (LST) sector, ...

Hollow Brook Wealth Management sold its entire position in Bio-Techne -- 174,677 shares -- during the fourth quarter of 2025, for an estimated $10.7 million based on quarterly average pricing. The ...